Mirae Asset Capital Life Science

Mirae Asset Capital Life Science operates as a dedicated venture capital platform under Mirae Asset Financial Group, a publicly traded South Korean financial services firm. It functions as the group's primary vehicle for early-stage life sciences investing in the United States. The parent company provides strategic backing and access to Asian distribution networks.

The firm concentrates on early-stage venture and growth equity investments, with deals commonly in Seed through Series B rounds. It focuses on companies developing novel therapeutics, medical devices, and diagnostics. Later-stage participation occurs selectively through follow-on financings for existing portfolio holdings.

Yes, a key feature of the platform is its ability to connect US-based portfolio companies with commercial partners and regulatory pathways in South Korea and broader Asia. This is facilitated through Mirae Asset Financial Group's established presence and relationships in the region, offering a differentiated value proposition compared to standalone US venture funds.

The firm's investment activity concentrates on North America, with its office in the Boston biotech corridor. While primarily US-focused for deal origination, the strategic mandate includes supporting portfolio company expansion into Asian markets by utilizing the parent group's cross-border infrastructure.

The firm is exclusively focused on life sciences and healthcare, avoiding sectors outside biotechnology, pharmaceuticals, medical technology, and digital health. It does not participate in generalist technology, consumer, or industrial venture investments, maintaining a dedicated sector mandate aligned with the parent group's strategic healthcare allocation.